<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772289</url>
  </required_header>
  <id_info>
    <org_study_id>MCHHFoshan-1602</org_study_id>
    <nct_id>NCT02772289</nct_id>
  </id_info>
  <brief_title>Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maternal and Child Health Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maternal and Child Health Hospital of Foshan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells
      treatment on the appearance of a caesarean scar as compared to a similar untreated scar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays, cesarean is one of the most common surgical interventions and its prevalence has
      increased in most countries in the recent years. Delay in healing of cesarean wound and
      formation of visible scar are common symptoms of maternal morbidity after cesarean section.
      These complications affect mother's quality of life due to stress, anxiety, delay in mother's
      ability and health recovery, and also they are associated with additional cost as a result of
      the increased need for wide spectrum antibiotics and sometimes hospitalization and repeated
      repair of wound. Improve the final aspect of would and visible scars, have been a challenge
      for medicine. Mesenchymal stem cells (MSC) are a population of pluripotent stem cells that
      are self-renewing and capable of differentiating into canonical cells of the mesenchyme.
      Recently, stem cells have been applied to regenerative medicine, even for internal organs
      such as blood vessels, nerves, and heart.

      The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells
      treatment on the appearance of a caesarean scar as compared to a similar untreated scar. This
      is a randomized, double-blind, placebo-controlled clinical trial designed to investigate the
      efficacy and safety of perinatal tissue mesenchyme stem cells (MSC) treatment on the
      appearance of a caesarean scar as compared to a similar untreated scar. A total of ninety
      (90) participants will be randomized (1:1:1) to receive MSC or placebo. All of participants
      will be undergoing delivery by lower segment caesarean section through a transverse abdominal
      incision, and there will be no clear indication for a particular surgical technique or
      material to be used. In low-dose MSC group, participants will receive transdermal one dose of
      1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous
      three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem
      Cells in the gel once a day for continuous next three days; In high-dose MSC group,
      participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme
      Stem Cells in the gel once a day for continuous six days; And in placebo group, participants
      will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel
      once a day for continuous six days. After randomization, baseline data, and transdermal
      treatment, participants will be followed up at 1 month, 3 months and 6 months. For the
      purpose of the endpoint analysis and safety evaluations, the investigators will utilize an
      &quot;intention-to-treat&quot; study population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Vancouver Scar Scale (VSS)</measure>
    <time_frame>1st, 3rd, 6th month post treatment</time_frame>
    <description>The investigators measured quartile grading scale at 1st, 3rd and 6th months of study and evaluated the change of the scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing status</measure>
    <time_frame>14 days post surgery</time_frame>
    <description>Wound healing status was assessed using REEDA scale which is based on the amount of redness, edema, ecchymosis, discharge and the approximation of wound edges (each one scored between 0-3); the final score was the sum of the items scores. Lower score indicated better healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema measured by reflectance</measure>
    <time_frame>1st, 3rd, 6th month post treatment</time_frame>
    <description>measured by reflectance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigmentation measured by reflectance</measure>
    <time_frame>1st, 3rd, 6th months post treatment</time_frame>
    <description>measured by reflectance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scar Thickness and Uniformity</measure>
    <time_frame>1st, 3rd, 6th month post treatment</time_frame>
    <description>A High Definition Ultrasound (US) device will be used to generate a high resolution image of the skin layers of the treated and non-treated scar in order to measure and compare changes in scar thickness and uniformity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of scar area</measure>
    <time_frame>1st, 3rd, 6th month post treatment</time_frame>
    <description>A High Definition Ultrasound (US) device will be used to generate a high resolution image of the skin layers of the treated and non-treated scar in order to measure and compare changes in scar area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin concentrations in breast milk</measure>
    <time_frame>1st, 3rd, 6th month post treatment</time_frame>
    <description>Breast milk immunoglobulin (IgG, IgA, IgM) and the complement (C3, C4) were detected by transmission immune turbidity method using automatic biochemical analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's satisfaction</measure>
    <time_frame>6th month post treatment</time_frame>
    <description>Subject's satisfaction of the treatment using a Satisfaction Scale as follows: None; Slight; Moderate; Good; Very Good.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events will be evaluated since the baseline visit until 6 months after the end of the treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cicatrix</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 3 million Mesenchymal Stem Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells high-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 6 million Mesenchymal Stem Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo without Mesenchyme Stem Cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchyme Stem Cells low-dose group</intervention_name>
    <description>Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.</description>
    <arm_group_label>Mesenchymal Stem Cells low-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchyme Stem Cells high-dose group</intervention_name>
    <description>Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.</description>
    <arm_group_label>Mesenchymal Stem Cells high-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primiparous women receiving cesarean delivery

          -  Ages between 21-35 years

          -  Gestation ages â‰¥ 37 weeks and &lt; 42 weeks

          -  Willing to give and sign an informed consent form and a photographic release form

          -  Willing to comply with study dosing and complete the entire course of the study

        Exclusion Criteria:

          -  Any systemic uncontrolled disease

          -  Recent or current cancer

          -  History or presenting with a keloid formation

          -  Wounds or local disease in treatment area

          -  Planning any other cosmetic procedure to the study area during the study period

          -  Smoking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhengping Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternal and Child Health Hospital of Foshan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhengping Liu, MD</last_name>
    <phone>+ 86 757 82969772</phone>
    <email>liuzphlk81@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dazhi Fan, MD</last_name>
    <phone>+ 86 757 82969772</phone>
    <email>fdz1988@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deqin Jia</last_name>
      <phone>+ 86 757 82969772</phone>
      <email>trials_fs_mchh@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Dazhi Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maternal and Child Health Hospital of Foshan</investigator_affiliation>
    <investigator_full_name>Zhengping Liu, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Mesenchyme Stem Cells</keyword>
  <keyword>Cesarean Section</keyword>
  <keyword>Scars</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

